ストックスクリーナーアプリを入手
7.05
2.22%
-0.16
アフターアワーズ：
7.05
Bioage Labs Inc (BIOA) 最新ニュース
BioAge Labs to Present at Upcoming Investor Conferences - markets.businessinsider.com
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection? - stocktwits.com
BIOAGE Labs Inc (BIOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAge Labs at Morgan Stanley conference: BGE-102 gains focus - Investing.com
Analysts Offer Insights on NA Companies: Fair Isaac (FICO), Freeport-McMoRan (FCX) and BioAge Labs, Inc. (BIOA) - theglobeandmail.com
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
BioAge Labs at Cantor conference: shifts focus to retina By Investing.com - Investing.com Canada
Transcript : BioAge Labs, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11 - marketscreener.com
BIOA: Phase II trials for BGE-102 target DME and metabolic diseases, with pivotal data expected next year - TradingView
BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema - The Manila Times
A daily pill for diabetic eye disease enters a Phase 2 trial - Stock Titan
BioAge Labs remains a buy despite 40% drop, bac... - Pluang
BioAge: CV Risk Data Due H2 A Major Catalyst After Rival's Data Causes Sell-Off (BIOA) - Seeking Alpha
Bioage Labs Market Sentiment - Benzinga España
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know - qz.com
BIOA Q2 2026 Earnings: Narrower-Than-Expected Loss Underscores Clinical-Stage DisciplineEarnings Volatility Report - dars.gov.et
354,395 Shares in BioAge Labs, Inc. $BIOA Bought by Walleye Capital LLC - MarketBeat
BioAge Labs, Inc.: Shareholders Board Members Managers and Company Profile | US09077V1008 - marketscreener.com
Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan
214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat
BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo
BioAge Labs (BIOA) Retreats 2.3% Toward Key Support as Momentum FadesVolatility Term Structure - careplusvn.com
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Hold Rating, Cuts Target Price to $20 - Moomoo
Roth MKM Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV) - The Globe and Mail
BIOA News & Events - Intellectia AI
BIOAGE Labs Inc (BIOA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BIOAGE Labs Inc (BIOA) Stock News Today - TradingKey
A Quick Look at Today's Ratings for BioAge Labs(BIOA.US), With a Forecast Between $21 to $73 - Moomoo
BioAge Labs, Inc. Stock 12‑Month Price Target Cut to $35.62, Implies 224% Upside - TradingView
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
BioAge Labs (NASDAQ:BIOA) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
BioAge Labs, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
BIOA: BGE-102 clinical trials advanced, net loss increased, and cash reserves remain strong - TradingView
BioAge Labs reports Q2 2026 net loss $26.1M, cash and securities $381.3M; BGE-102 Phase 2 dosing underway - TradingView
BioAge Labs, Inc. Q2 2026: Revenue $2.45M, EPS $(0.58) — 10-Q Summary - TradingView
BioAge Labs (NASDAQ: BIOA) builds $381.3M cash buffer as BGE-102 advances - Stock Titan
BioAge Labs | 10-Q: Q2 2026 Earnings Report - Moomoo
BioAge Labs Reports Q2 2026 Results, Doses First Patient in QUELL-CV and Advances BGE-102 Clinical Development - Quiver Quantitative
BioAge Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BioAge's BGE-102 Enters Obesity Trial; Eye Study Planned - Stock Titan
Price to earnings forward of BioAge Labs, Inc. – SWB:Y7G - TradingView
BIOA Q2'26 Earnings: revenue estimate is 1.50M USD - TradingView
Piper Sandler Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $73 - Moomoo
BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ) - Seeking Alpha
Weekly Recap: ZEUS miss lifts BGE-102 and Analysts cut BIOA PTs, keep Buy - TradingView
Janus Henderson Group PLC Acquires 1,685,063 Shares of BioAge Labs, Inc. $BIOA - MarketBeat
BTIG Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Why is BioAge Labs stock plunging today? By Investing.com - Investing.com Canada
BIOAGE LABS INC : NEEDHAM CUTS TARGET PRICE TO $35 FROM $50 - Bitget
BioAge Labs (BIOA) Surges 12% as Momentum Builds Past Key Support LevelOversold Bounce Ideas - vinanet.vn
BIOA|BIOAGE Labs Inc|Price:20.850|Chg%:-0.920 - TradingKey
BIOAGE Labs Inc (BIOA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BIOAGE Labs Inc (BIOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BIOAGE Labs Inc (BIOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BioAge Labs, Inc. $BIOA Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Has $30.57 Million Stock Position in BioAge Labs, Inc. $BIOA - MarketBeat
The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BI - GuruFocus
BIOAGE Labs Inc (BIOA) Income Statement - TradingKey
TradingKey - TradingKey
BIOAGE Labs Inc (BIOA) Balance Sheet - TradingKey
0.18%
0.69%
大文字化:
|
ボリューム (24 時間):